PT  - JOURNAL ARTICLE
AU  - Sourij, Caren
AU  - Tripolt, Norbert J
AU  - Aziz, Faisal
AU  - Aberer, Felix
AU  - Forstner, Patrick
AU  - Obermayer, Anna M
AU  - Kojzar, Harald
AU  - Kleinhappl, Barbara
AU  - Pferschy, Peter N
AU  - Mader, Julia K
AU  - Cvirn, Gerhard
AU  - Goswami, Nandu
AU  - Wachsmuth, Nadine
AU  - Eckstein, Max L.
AU  - Müller, Alexander
AU  - Abbas, Farah
AU  - Lenz, Jacqueline
AU  - Steinberger, Michaela
AU  - Knoll, Lisa
AU  - Krause, Robert
AU  - Stradner, Martin
AU  - Schlenke, Peter
AU  - Sareban, Nazanin
AU  - Prietl, Barbara
AU  - Kaser, Susanne
AU  - Moser, Othmar
AU  - Steinmetz, Ivo
AU  - Sourij, Harald
AU - on behalf of the COVAC-DM study group
TI  - Humoral immune response to Covid-19 vaccination in diabetes: age-dependent but independent of type of diabetes and glycaemic control – the prospective COVAC-DM cohort study
AID  - 10.1101/2021.11.05.21265849
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.05.21265849
4099  - http://medrxiv.org/content/early/2021/11/09/2021.11.05.21265849.short
4100  - http://medrxiv.org/content/early/2021/11/09/2021.11.05.21265849.full
AB  - Aims Immune response to COVID-19 vaccination and a potential impact of glycaemia on antibody levels in people with diabetes remains unclear. We investigated the seroconversion following first and second COVID-19 vaccination in people with type 1 and type 2 diabetes in relation to glycaemic control prior to vaccination and analysed the response in comparison to individuals without diabetes.Materials and Methods This prospective, multicenter cohort study analysed people with type 1 and type 2 diabetes, well (HbA1c<7.5% or <58 mmol/mol) or insufficiently (HbA1c≥7.5% or ≥58 mmol/mol) controlled and healthy controls. Roche’s Elecsys anti-SARS-CoV-2 S was used to quantify anti-spike protein antibodies 7-14 days after the first and 14-21 days after the second vaccination.Results 86 healthy controls and 161 participants with diabetes were enrolled, 150 (75 with type 1 diabetes and 75 with type 2 diabetes) were eligible for the analysis. After the first vaccination, only 52.7% in the type 1 diabetes group and 48.0% in the type 2 diabetes group showed antibody levels above the cut-off for positivity. Antibody levels after the second vaccination were similar in people with type1, type 2 diabetes and healthy controls if adjusted for age, sex and multiple testing (p>0.05). Age (r=−0.45, p<0.001) and glomerular filtration rate (r=0.28, p=0.001) were significantly associated with antibody response.Conclusions Anti-SARS-CoV-2 S antibody levels after the second vaccination were comparable in healthy controls, people with type 1 and type 2 diabetes, irrespective of glycaemic control. Age and renal function correlated significantly with the extent of antibody levels.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialEU Clinical Trials Register: 2021-001459-15Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the ethics committees of the Medical University of Graz (33-366 ex 20/21) and the Bayerische Landesaerztekammer (Nr. 21031)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors